Zealand Pharma A/S
Glucagon-GLP-1-GIP triple agonist compounds
Last updated:
Abstract:
The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
Status:
Grant
Type:
Utility
Filling date:
4 Oct 2018
Issue date:
7 Sep 2021